A Randomized, Placebo Controlled Phase 2B/3 Study Of Abt-414 With Concurrent Chemoradiation And Adjuvant Temozolomide In Subjects With Newly Diagnosed
Posted Date: May 15, 2019
- Investigator: Rekha Chaudhary
- Type of Study: Drug
The main purposes of this study are to evaluate whether combining ABT-414 with usual RT and TMZ treatment controls GBM better than usual RT and TMZ without ABT-414, and whether ABT-414 makes patients live longer. This study will only include people whose tumors are tested and confirmed to have EGFR
Criteria:
To Be Eligible For This Study, Patients Must Have Been Diagnosed With A Glioblastoma (Brain Tumor).
Keywords:
M13-813, Glioblastoma, Brain, Egfr1, Cancer
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu